Product

experienced improved glycemic parameters, reduced hemoglobin A1c levels, and enhanced lipid profiles. These findings indicate that GLP-3 (RTA) could be a groundbreaking therapeutic option for metabolic disorders (Kapitza et al., 2023). Further investigations are ongoing to assess GLP-3 (RTA) long-term safety, potential cardiovascular benefits, and its effects on metabolic syndrome components. If proven effective and safe in large-scale trials, GLP-3 (RTA) may represent a new frontier in the treatment of obesity and diabetes, addressing multiple pathways of metabolic dysfunction simultaneously (Tschöp et al., 2023).